SSDLC for Medical Device Cybersecurity

Part of our medtech cybersecurity framework choice series (SPDF, JSP2, IEC 81001-5-1). For the full overview, start with JSP2 vs SPDF vs IEC 81001-5-1: Framework Pick.

Updated November 10, 2024

Why this matters

A medical device can perform its intended function and still accept an unauthorized configuration change or malicious firmware update. Functional correctness alone does not establish security. We need evidence that the device resists misuse and behaves safely when a connection, component, or control fails.

The FDA's Cybersecurity in Medical Devices Final Guidance, dated February 3, 2026, emphasizes security throughout the product lifecycle. An SSDLC turns that expectation into development work: requirements, architecture decisions, implementation checks, security tests, and postmarket processes.

IEC 81001-5-1, ISO/IEC 27001, and AAMI TIR57 / ANSI/AAMI SW96:2023 provide relevant frameworks, but they serve different purposes. Following an SSDLC does not automatically establish conformity with any of them. Manufacturers still need to identify applicable requirements and produce evidence against them.

The stakes include patient harm, operational disruption, exposed health information, and expensive field remediation. Regulatory noncompliance can also restrict market access and, depending on the underlying violation, lead to enforcement or penalties. Security work belongs in the development schedule, not in a document sprint before submission.

Understanding the Importance of Cybersecurity in Medical Devices

Connected medical devices depend on more than their embedded code. Companion apps, hospital networks, cloud services, update servers, and third-party software can all affect device security. We assess those dependencies because a control inside the device may not protect an attack path through another component.

Artificial intelligence and machine learning add further concerns. Protecting access to a model is not the same as protecting its training data, inputs, or outputs. Threat modeling must account for how those elements affect clinical use.

A breach can jeopardize patient safety, but “patient safety” should not be a generic impact statement. We need to identify what an attacker could change, interrupt, or disclose, then connect that effect to the device's use and safety risk assessment. Healthcare providers also have responsibilities, including secure configuration, staff training, and response procedures. Those responsibilities need usable manufacturer instructions.

The Role of Medical Devices in Healthcare

Medical devices support diagnosis, monitoring, and treatment. Heart monitors help clinicians recognize changes in a patient's condition. Wireless capabilities in pacemakers and defibrillators support remote monitoring, particularly for patients with chronic conditions.

Those benefits create security dependencies. A monitoring function depends on trustworthy measurements and timely delivery. A remote connection needs access controls and protection for transmitted health data. We therefore ask not only whether data is encrypted, but whether clinicians can distinguish current information from stale, missing, or altered information.

The Growing Threat of Cyber Attacks

Healthcare remains an attractive target for attackers seeking financial gain or sensitive data. Ransomware has disrupted hospital operations and delayed care. A device does not need to be the initial entry point to suffer the consequences of an attack on its environment.

Interconnected systems can also let a compromise spread. That is why we assume the network may be hostile rather than treating an internal connection as trusted. Segmentation reduces exposure; it does not replace authentication, authorization, or secure update controls on the device itself.

The useful planning question is not whether an attack is inevitable. It is whether the manufacturer understands reachable attack paths and has tested the controls intended to block them.

An Introduction to Secure Software Development Life Cycle (SSDLC)

An SSDLC integrates security activities into software development and maintenance. It is not a separate paperwork process and it is not a substitute for engineering judgment.

We look for defined inputs and outputs at each phase. A threat should lead to a security requirement. The requirement should influence implementation. Testing should produce evidence against that requirement, and unresolved risk should reach an accountable decision-maker before release.

The Five Phases of SSDLC

The five phases below describe the development cycle. Maintenance feeds findings and changes back into that cycle rather than ending at deployment.

1. Requirement Analysis: Identify assets, intended use, interfaces, foreseeable misuse, and security requirements. Define acceptance criteria and assign owners.
2. Design: Incorporate security architecture by design. Map data flows and trust boundaries, identify threats, and choose controls while architecture decisions can still change.
3. Implementation: Apply secure coding standards, code review, and static application security testing. Track third-party dependencies and generate an SBOM that corresponds to the build.
4. Testing: Exercise security requirements and attack paths through appropriate security testing, including penetration testing and fuzzing. Document findings, remediation, and retest results.
5. Deployment: Release with secure configuration instructions, a working update mechanism, vulnerability monitoring, and coordinated disclosure procedures. Feed postmarket findings into risk management and future releases.

The Benefits of Implementing SSDLC

The main benefit is earlier decision-making. Changing an authentication design before implementation is usually less disruptive than replacing it after devices reach the field. Early work can reduce rework, downtime, and remediation costs.

An SSDLC also makes submission preparation more predictable. Instead of reconstructing why a control exists, the manufacturer can follow the record from threat to requirement to test result.

There is an organizational benefit, too. Developers, security specialists, quality staff, and regulatory staff work from the same evidence. Security stops being a late review owned by someone outside the development process. That can improve software quality and customer trust, but only if teams act on findings rather than treating completed documents as the outcome.

The Intersection of SSDLC and Medical Device Cybersecurity

For a medical device, security decisions must account for clinical use. Lockout behavior, connection loss, update timing, and recovery procedures can affect care. A control that blocks an attacker but prevents needed access may create a different risk.

We use the SSDLC to make those tradeoffs visible before release. Security risk management and safety risk management need connected evidence, not interchangeable terminology.

How SSDLC Enhances Medical Device Security

On a Class II wearable we tested, firmware updates arrived over BLE through a companion app. The bootloader checked a CRC but did not verify a cryptographic signature. We replayed a captured image with a one-byte modification; the device installed it and rebooted into the modified firmware.

That finding belongs in more than the penetration test report. It points back to the update requirements and bootloader design. The recommended remediation was ECDSA P-256 image signing, signature verification before commit, a public key in write-protected storage, and a monotonic version counter to resist rollback. A CRC can detect accidental corruption. It does not establish who authorized an image.

This is what an SSDLC should connect: the threat, the missing requirement, the implementation change, and the test that checks the fix. Regular security assessments then keep that evidence current as software, dependencies, and deployment conditions change.

Addressing Potential Challenges in Implementation

Time, staffing, tooling, and resistance to new workflows are real constraints. Adding security tasks without assigning ownership or allowing time to fix findings will not solve them.

We recommend starting with the existing development process. Put threat review into design reviews, dependency checks into build workflows, and security acceptance criteria into release decisions. Train people for the decisions they own rather than giving everyone the same generic awareness session.

This is the part teams skip: reserve time for remediation and retesting. Finding a defect near release does not make it a testing problem. It exposes a scheduling and risk-acceptance problem that the process needs to handle.

Regulatory Compliance and SSDLC

An SSDLC supports regulatory compliance by producing evidence as development proceeds. It does not prove compliance merely because the organization has a written procedure.

See also: Secure Software Development for Medical Devices, and SPDF Cybersecurity Documentation.

We look for records that answer practical review questions: What threats were identified? Which requirements address them? What was tested? What remains unresolved? Who accepted the residual risk, and on what basis?

Those records also support audits, onboarding, and changes to the product. They let a new engineer understand why a control exists without relying on the memory of its original designer.

Meeting FDA Cybersecurity Guidelines with SSDLC

In the FDA letters we reviewed for our September 2026 MTEC webinar, one submission received nine separate findings for controls described only at a high level. The recurring problem was not a lack of security terminology. It was a lack of specification-level detail, such as a password policy, TLS cipher suites, or the curve and hash function used with ECDSA.

An SSDLC should catch that gap during requirements review. “The device authenticates users” is an intent statement. It does not define enough behavior for a meaningful pass or fail test.

We recommend tracing each control to a requirement identifier, a test case, and a result. The submission should also explain unresolved findings and residual risk. A folder of reports without those connections makes the reviewer reconstruct the manufacturer's argument.

This approach supports the FDA's February 3, 2026 final guidance. It does not guarantee clearance or eliminate the possibility of additional questions.

International Standards for Medical Device Cybersecurity

Beyond the FDA, manufacturers need to account for the requirements of their target markets. International standards can provide reusable structure, but they are not interchangeable approvals.

ISO/IEC 27001 addresses an organization's information security management system. IEC 81001-5-1 addresses security activities across the health software product lifecycle. AAMI TIR57 and ANSI/AAMI SW96:2023 address medical device security risk management.

We recommend mapping applicable provisions to SSDLC activities and evidence. That makes gaps visible and can reduce duplicated work across markets. Demonstrated conformity may also support customer confidence and commercial partnerships, but the underlying goal remains defensible security and patient protection.

Future Trends in Medical Device Cybersecurity

Devices may remain in service while their dependencies, operating environments, and threats change. Future readiness therefore depends less on predicting the next attack than on retaining the ability to assess, update, and support a fielded product.

We treat component support status, cryptographic choices, update capability, and end-of-life planning as development decisions with long-term consequences.

Predicted Developments in Cyber Threats

Attack techniques will continue to change as devices add connectivity and software capabilities. The Internet of Medical Things (IoMT) expands the number of interfaces and dependencies that manufacturers and healthcare providers must manage. A weakness in one connected component can affect others, although the extent depends on architecture and access controls.

AI-enabled devices need more specific analysis. In the FDA letters we reviewed for our September 2026 MTEC webinar, data poisoning, model inversion, and model evasion were consistently absent from the threat models for the AI-enabled devices in the set. That observation comes from the reviewed sample, not an industry-wide rate. It shows why a generic network threat model may miss threats introduced by a product's actual technology.

Quantum computing is another longer-term concern, particularly for cryptography and data that must remain confidential for many years. We would not let speculative threats displace reachable attack paths today. We would use lifecycle planning to identify cryptographic dependencies and the ability to replace them.

The Role of SSDLC in Future Cybersecurity Strategies

A useful SSDLC can absorb new information. A newly disclosed component vulnerability should trigger an applicability assessment, risk evaluation, and a documented response. A new interface or model capability should trigger a threat-model review.

Training also needs to continue. Developers and engineers need time to learn relevant attack techniques, review failures, and practice response decisions through workshops and simulations.

The objective stays constant: protect patients and their information while allowing devices to improve. The process must support that objective after deployment, not just through the submission date.

Conclusion

An SSDLC is effective when it changes engineering decisions and preserves the evidence behind them. Start with specific threats and requirements. Test the controls. Resolve findings or document the residual risk. Keep the update and monitoring processes working after release.

We would prioritize traceability over adding more documents. A short, connected record of what was designed, tested, and accepted is more useful than pages of security principles with no supporting results.

Blue Goat Cyber provides medical device security testing, threat modeling, security risk management, SBOM work, architecture views, and regulatory submission support. Our premarket service includes retesting to verify remediation within its scope, and fixed-fee engagements can be scoped for the device's attack surfaces. Those services support the manufacturer's evidence package; they do not guarantee a regulatory outcome.

Contact us today for cybersecurity help, and let Blue Goat Cyber be the partner you need for a secure future in digital healthcare.

How Blue Goat approaches this

We test against the device's threat model rather than a generic checklist. The scope needs to cover the relevant interfaces and trust boundaries, including wireless links, companion apps, and supporting infrastructure where applicable.

Our security testing reports document scope, methodology, reproduction steps, risk-rated impact, recommended remediation, and traceability to the device's risk file. Retesting checks whether the remediation addresses the finding. This is security testing, not a replacement for the manufacturer's verification and validation responsibilities.

At our September 17, 2026 secure-by-design workshop in Singapore, we used an illustrative wireless device example to connect spoofing during unauthenticated pairing to a per-device certificate control and a penetration test that checks rejection of an unauthenticated device. It was a teaching example, not a client engagement. The point was the connection between artifacts: a named threat, a specified control, and evidence that exercises it.

Learn more about our testing scope at Medical Device Penetration Testing.

Related reading: SaMD vs SiMD: What Medical Device Manufacturers Need to Know.

FAQ

What is SSDLC in the context of medical devices?

SSDLC means Secure Software Development Life Cycle. It integrates security requirements, design decisions, implementation checks, testing, and maintenance into medical device software development. We use it to connect security work to product decisions and evidence, rather than leaving it until submission.

How does SSDLC help medical device manufacturers comply with FDA guidance?

SSDLC supports the FDA's February 3, 2026 final guidance by building security requirements, risk management, testing, and postmarket planning into development. It helps produce traceable documentation, but manufacturers must still assess applicable requirements and address evidence gaps.

What are the common challenges when implementing SSDLC for medical devices?

Common challenges include limited staff and time, resistance to workflow changes, and pressure to release before security findings are resolved. We recommend assigning owners, integrating checks into existing reviews, and budgeting for training, remediation, and retesting.

When should security be considered in the medical device development process?

Start during requirement analysis, while security findings can still change the design. Identify assets, interfaces, trust boundaries, and foreseeable misuse before architecture decisions become expensive to revise.

Does SSDLC apply to existing medical devices?

Yes. Manufacturers can apply SSDLC practices to updates, patches, vulnerability monitoring, and maintenance of existing devices. Legacy constraints may limit remediation options, so the process should document those limits and connect them to risk decisions and support planning.

Why is rigorous testing important in the SSDLC for medical devices?

Security testing checks whether implemented controls resist relevant attack paths. It can expose weaknesses before release and provide evidence for remediation and risk assessment. Testing supports patient safety and data protection, but a passing result does not prove that no vulnerabilities remain.

Related: A Guide to Software Testing for Medical Devices